BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 26, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 3, 2010
View Archived Issues
Suven Life Sciences presents new agents with encouraging in vivo procognitive activity
Read More
Auspex Pharmaceuticals claims deuterated SGLT-2 inhibitors
Read More
Abbott discloses new HCV serine protease NS3 inhibitors
Read More
Merck & Co. launches Dulera in U.S. for asthma
Read More
Results reported on Basilea's Toctino in severe chronic hand eczema
Read More
PAION advances phase IIb trial of anesthetic/sedative remimazolam
Read More
BrainStorm and Hadassah to begin phase I/II trial of NurOwn technology platform candidate in ALS
Read More
ACT submits response to FDA regarding phase I/II MA-09-HRPE trial in eye disease
Read More
Prolactin receptor expression is potential biomarker for colorectal cancer progression
Read More
Methylation state of HOXD3 gene identified as biomarker for prostate cancer
Read More
Promising preliminary phase II data disclosed on HIV immunotherapeutic AGS-004
Read More
Conatus Pharmaceuticals acquires Idun Pharmaceuticals from Pfizer
Read More
FDA confirms orphan drug exclusivity of Wilate for von Willebrand's disease
Read More
Astellas and Kotobuki disclose new SGLT-1 and SGLT-2 inhibitors
Read More
German scientists identify new HIF-1-alpha inhibitors
Read More
Dainippon Sumitomo Pharma presents new Na(V)1.8 channel inhibitors
Read More
Cardioxyl reports phase I/IIa data on CXL-1020 in heart failure
Read More
Servier to develop and commercialize Osteologix's NBS-101 outside U.S.
Read More
Repligen receives funds to develop HDAC inhibitors in Friedreich's ataxia and HD
Read More
FDA approves Xeomin for cervical dystonia and blepharospasm
Read More
Quest Diagnostics' XSense test for fragile X syndrome approved in New York state
Read More
ArQule and Daiichi Sankyo advance ARQ-197 to phase III in non-small cell lung cancer
Read More
BioMarin reports topline phase II data on PEG-PAL in PKU
Read More
BioMarin discontinues development of BMN-195
Read More
Reduced TSPO expression and low progesterone are linked to MDD
Read More
